Latest Information Update: 27 Jun 2002
At a glance
- Originator Mitsubishi Pharma Corporation
- Mechanism of Action Chymase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 31 Aug 2000 New profile
- 31 Aug 2000 Preclinical development for Atopic dermatitis in Japan (Unknown route)